299 related articles for article (PubMed ID: 20100048)
1. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities.
Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C
Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
[TBL] [Abstract][Full Text] [Related]
3. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP).
Knorr C; Melling N; Goehl J; Drachsler T; Hohenberger W; Meyer T
Int J Hyperthermia; 2008 Aug; 24(5):409-14. PubMed ID: 18608587
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
6. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities.
Papa MZ; Klein E; Karni T; Koller M; Davidson B; Azizi E; Ben-Ari G
Am J Surg; 1996 Apr; 171(4):416-20. PubMed ID: 8604833
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic hyperthermic limb perfusion in stage I melanoma.
Krige JE; King HS; Strover RM
Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
[TBL] [Abstract][Full Text] [Related]
9. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
10. Results of hyperthermic perfusion for melanoma of the extremities.
Stehlin JS; Giovanella BC; de Ipolyi PD; Muenz LR; Anderson RF
Surg Gynecol Obstet; 1975 Mar; 140(3):339-48. PubMed ID: 1114425
[TBL] [Abstract][Full Text] [Related]
11. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
12. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
[TBL] [Abstract][Full Text] [Related]
15. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
17. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.
Sanki A; Kam PC; Thompson JF
Ann Surg; 2007 Apr; 245(4):591-6. PubMed ID: 17414608
[TBL] [Abstract][Full Text] [Related]
19. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma.
Fletcher WS; Pommier R; Small K
Melanoma Res; 1994 Mar; 4 Suppl 1():17-9. PubMed ID: 8038590
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
